The global genome editing market size was valued at USD 7.98 billion in 2023 and is predicted to reach around USD 38.19 billion by 2033. The market is expanding at a solid CAGR of 16.95% from 2024 to 2033.
Key Points
- The North America genome editing market size reached USD 3.83 billion in 2023 and is expected to attain around USD 18.52 billion by 2033, poised to grow at a CAGR of 17.06% between 2024 and 2033.
- North America led the market with the largest revenue share of 48% in 2023.
- Asia Pacific is expected to expand at a solid CAGR of 18.75% during the forecast period.
- By technology, the CRISPR/Cas9 segment has contributed more than 45% of revenue share in 2023.
- By technology, the ZFN segment is projected to grow at a notable CAGR of 16.57% during the forecast period.
- By delivery methods, the ex-vivo segment has held a major revenue share of 52% in 2023.
- By delivery methods, the in-vivo segment is expected to grow with the highest CAGR of 19.24% during the forecast period.
- By application, the genetic engineering segment dominated the market in 2023.
- By application, the clinical applications segment is estimated to expand at the solid CAGR of 13.20% during the forecast period.
- By mode, the contract segment led the market in 2023.
- By mode, the in-house segment is expected to be the fastest-growing segment in the market.
- By end-use, the biotechnology and pharmaceutical companies segment has held a biggest revenue share of 51% in 2023.
- By end-use, the academic and research institutions segment is estimated to at a remarkable CAGR of 19.23% during the forecast period.
The genome editing market involves technologies and methodologies used to alter the genetic material of organisms to achieve desired traits. It encompasses tools like CRISPR-Cas9, TALENs, and ZFNs, which allow for precise and targeted modifications in DNA. Applications range from agriculture to medicine, where genome editing is used for creating genetically modified crops, developing gene therapies, and conducting biomedical research. The market is characterized by rapid technological advancements, increasing investment in biotechnology research, and growing collaborations between academic institutions and biopharmaceutical companies.
Get a Sample: https://www.precedenceresearch.com/sample/4563
Growth Factors
Key growth factors driving the genome editing market include the rising prevalence of genetic disorders, increasing funding for genetic research, and advancements in genome editing technologies. The potential of these technologies to provide treatments for previously incurable diseases is a significant driver. Additionally, the expanding applications in agriculture to create crops with better yields and resistance to pests and environmental stress contribute to market growth. The decreasing cost of genome sequencing and editing technologies also makes these tools more accessible to a broader range of researchers and companies.
Region Insights
North America dominates the genome editing market due to robust research infrastructure, significant government funding, and the presence of leading biotechnology companies. Europe follows closely, driven by substantial investments in research and development and favorable regulatory frameworks. The Asia-Pacific region is witnessing rapid growth, fueled by increasing investments in biotechnology, rising awareness of genome editing’s potential, and supportive government policies in countries like China and India. Latin America and the Middle East are also emerging markets with growing interest and investment in genetic research and biotechnology.
Genome Editing Market Scope
| Report Coverage | Details |
| Market Size by 2033 | USD 38.19 Billion |
| Market Size in 2023 | USD 7.98 Billion |
| Market Size in 2024 | USD 9.33 Billion |
| Market Growth Rate from 2024 to 2033 | CAGR of 16.95% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Technology, Delivery Method, Application, Mode, End-use, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Genome Editing Market Dynamics
Drivers
The primary drivers of the genome editing market include technological advancements, the growing burden of genetic diseases, and the increasing adoption of gene therapy. Technological innovations, particularly the development of CRISPR-Cas9, have revolutionized genome editing by making it more efficient, accurate, and cost-effective. The rise in genetic disorders and the need for personalized medicine drive the demand for genome editing technologies. Additionally, the agricultural sector’s demand for genetically modified crops to ensure food security and sustainability further propels market growth.
Opportunities
Significant opportunities in the genome editing market lie in the development of new therapies for genetic disorders, cancer, and other diseases. The agricultural sector also presents opportunities for creating crops with enhanced traits such as increased yield, nutritional value, and resistance to pests and environmental conditions. Collaborations and partnerships between research institutions, biotechnology companies, and government bodies can accelerate advancements and expand the applications of genome editing technologies. Furthermore, the emerging field of synthetic biology, which involves designing and constructing new biological parts and systems, offers potential growth avenues.
Challenges
The genome editing market faces several challenges, including ethical and regulatory concerns, off-target effects, and the high cost of development. Ethical issues surrounding the modification of human embryos and potential long-term consequences of genetic alterations pose significant hurdles. Regulatory frameworks vary across regions, leading to inconsistencies in approval processes and commercialization. Off-target effects, where unintended parts of the genome are altered, remain a concern for the safety and efficacy of genome editing. Additionally, the high cost of developing genome editing technologies and therapies can limit their accessibility and widespread adoption.
Read Also: Custom Antibody Market Size to Reach USD 444.66 Million by 2033
Genome Editing Market Companies
- Merck KGaA.
- Cibus Inc.
- Recombinetics
- Sangamo Therapeutics
- Cellectis S.A.
- AstraZeneca
- Takara Bio Inc.
- Horizon Discovery Ltd. (Revvity, Inc.)
- Editas Medicine
- Precision BioSciences
- CRISPR Therapeutics
- Intellia Therapeutics, Inc.
- Caribou Biosciences, Inc
- Danaher Corporation
- Transposagen Biopharmaceuticals, Inc.
- Genscript Biotech Corp
- New England Biolabs
- OriGene Technologies, Inc.
- Bluebird Bio, Inc.
- Lonza
- Thermo Fisher Scientific, Inc
Recent Developments
- In April 2024, Regeneron Pharmaceuticals collaborated with Mammoth Biosciences. This collaboration is done to use Mammoth’s platform with Regeneron to develop in vivo therapies for tissues.
- In April 2024, Nvelop launched gene-editing cargo. Through this launch, Nvelop aimed to improve gene therapy delivery.
- In April 2024, Profluent launched an AI model that can generate CRISPR proteins. Through this launch, the company claimed that the usage of AI can create a large number of CRISPR proteins that help manufacture bespoke cures.
- In January 2024, Danaher Corporation collaborated with Innovative Genomics Institute (IGI). This collaboration aimed to develop gene editing therapies for the treatment of rare diseases and other diseases.
- In April 2023, Synthego Corp launched Express Knockout Cell Pools. This launch aimed to use Express Knockout Cell Pools for several research applications ranging from disease modelling to loss-of-function screens along with drug discovery.
Segments Covered in the Report
By Technology
- (CRISPR)/Cas9
- ZFN
- Meganuclease
- TALENs/MegaTALs
- Others
By Delivery Method
- Ex-vivo
- In-vivo
By Application
- Genetic Engineering
- Cell Line Engineering
- Plant Genetic Engineering
- Animal Genetic Engineering
- Others
- Clinical Applications
- Diagnostics
- Therapy Development
By Mode
- Contract
- In-house
By End-use
- Biotechnology and Pharmaceutical Companies
- Contract Research Organizations
- Academic And Government Research Institutes
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/
